Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.790
+0.340 (13.88%)
At close: Nov 1, 2024, 4:00 PM
2.731
-0.059 (-2.11%)
After-hours: Nov 1, 2024, 7:02 PM EDT
Aerovate Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 1, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 81 | 626 | 721 | 288 | - | - |
| Market Cap Growth | -89.89% | -13.15% | 150.50% | - | - | - |
| Enterprise Value | -23 | 492 | 580 | 108 | - | - |
| Last Close Price | 2.79 | 22.63 | 29.30 | 11.79 | - | - |
| PE Ratio | - | -7.89 | -13.92 | -6.31 | - | - |
| PB Ratio | 0.85 | 5.72 | 5.69 | 1.67 | - | - |
| P/FCF Ratio | -0.64 | -11.00 | -18.34 | -10.44 | - | - |
| P/OCF Ratio | -0.64 | -11.03 | -18.43 | -10.50 | - | - |
| EV/EBITDA Ratio | 0.54 | -6.05 | -10.90 | -4.67 | - | - |
| EV/EBIT Ratio | 0.54 | -6.04 | -10.89 | -4.67 | - | - |
| EV/FCF Ratio | 0.68 | -8.64 | -14.74 | -3.90 | - | - |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.00 | - | 7.00 |
| Debt / FCF Ratio | -0.01 | -0.01 | -0.03 | -0.02 | - | -0.90 |
| Quick Ratio | 6.12 | 6.94 | 16.60 | 65.64 | 2.58 | 5.35 |
| Current Ratio | 6.51 | 7.04 | 16.90 | 68.37 | 2.64 | 5.35 |
| Return on Equity (ROE) | -74.42% | -63.95% | -34.44% | -26.19% | -582.84% | - |
| Return on Assets (ROA) | -44.03% | -38.73% | -21.42% | -15.98% | -135.03% | - |
| Return on Capital (ROIC) | -49.51% | -42.76% | -22.12% | -16.36% | -191.64% | - |
| Earnings Yield | -109.18% | -12.06% | -7.15% | -7.98% | - | - |
| FCF Yield | -92.64% | -9.09% | -5.45% | -9.58% | - | - |
| Buyback Yield / Dilution | -13.63% | -7.60% | -99.06% | -4975.15% | -0.32% | - |
| Total Shareholder Return | -13.63% | -7.60% | -99.06% | -4975.15% | -0.32% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.